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assessed using Cronbach’s Alpha and evidence of construct valid-
ity was gained by relating CAMPHOR scores to NHP and EQ-
5D scores and the New York Heart Association Classiﬁcation
(NYHA). RESULTS: In total, 91 patients participated (mean
(SD)) age = 52.6 (16.0) years, 64% female, mean (SD) time since
diagnosis: 4.8 (6.0) years). All CAMPHOR scales obtained ade-
quate alpha coefﬁcients (0.90–0.92), indicating acceptable inter-
nal consistency and Spearman rank correlation coefﬁcients for
all CAMPHOR scales (0.86–0.92) indicated excellent repro-
ducibility. The CAMPHOR also exhibited discriminative valid-
ity, as the questionnaire was able to distinguish between patients
who differed according to self-perceived general health (p <
0.001), symptom level (p < 0.001) and NYHA classiﬁcation (p
< 0.001). The level of association was as expected, with more
closely related scales having higher levels of association (NHP
Energy Level with CAMPHOR Energy Level = 0.84; NHP 
emotional reactions and CAMPHOR mood = 0.84 and 
NHP physical mobility and CAMPHOR functioning = 0.85).
The EQ-5D also correlated most closely with CAMPHOR func-
tioning (0.74), which was anticipated, as 3 of the 5 EQ-5D items
relate to functioning. CONCLUSIONS: The results of the vali-
dation study provide evidence that the instrument will be able to
detect changes in HRQL and QoL occurring in routine clinical
practice and clinical trials, indicating that the CAMPHOR is a
valuable new instrument for assessing patient-reported outcome
in PAH.
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Isolated by language and cultural beliefs, Chinese immigrants
face formidable barriers to receiving appropriate health care ser-
vices. In the absence of preventive care, common treatable
disease such as high blood pressure (BP) becomes much more
dangerous and severe. OBJECTIVES: Assess trends in the preva-
lence, awareness, treatment, and control of hypertension among
Chinese immigrants in New York City (NYC). METHODS:
Using a standardized survey, BP measurements and health infor-
mation of participants aged 18 years or older were collected
during a series of community health fairs in various Chinese
communities. The 2001–2002 survey (N = 668) was compared
to 2003–2004 survey (N = 791). Hypertension is deﬁned as a
measured BP of >140/90mmHg or reported use of antihyper-
tensive medications. Hypertension awareness and treatment
were assessed with standardized questions. Hypertension control
was deﬁned as reported hypertension with or without antihy-
pertensive treatment and a measured BP of <140/90mmHg or
<130/85mmHg for diabetics. RESULTS: In 2003–2004, 44% of
participants had hypertension, a decrease of 5% (p = 0.058) from
2001–2002. Hypertension prevalence was higher in women
(25%) and increased with age (31% among those aged >60
years). In a Pearson correlation analysis, increasing age and
decreasing exercise were independently associated with increased
rates of systolic blood pressure (SBP) but not diastolic blood
pressure (DBP); increasing body mass index was independently
associated with increased in both SBP and DBP. Overall, in
2003–2004, 71% were aware of their hypertension (a decline of
1%; p < 0.737), 26% were treated (decrease of 8%; p = 0.017),
and hypertension was controlled in 40% (increase of 2%; p =
0.645). Men and those aged 40–59 had lower rates of hyper-
tension treatment and control compared with women and the
older individuals. CONCLUSIONS: Although prevalence and
control rates of hypertension are improving, hypertension
control rates continue to be low. Expanded effort is needed to
improve BP outcomes.
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OBJECTIVES: Visual analogue scaling (VAS) is a rating method,
widely used to estimate preferences for multi-attribute health
states. This study examines the ability of VAS preferences to dis-
criminate between severity levels in stroke-related disability
deﬁned by the Barthel Index (BI). METHODS: A community
sample of 152 adults (≥45 years) were instructed by trained
researchers to ﬁrst rank and then rate 14, 5-attribute disability
scenarios on a 20-point rating thermometer (0 = worst imagin-
able health state; 20 = best imaginable health state). Preferences
for Barthel Index disability scores were estimated from ordinary
least squares regression (OLS) and indexed on a scale of 0–1.
Discriminant validity of the VAS preferences was evaluated using
two BI severity categorization schemes, modiﬁed Rankin cate-
gories, and two BI endpoint categories used in clinical trials (<95
vs. ≥95 and <60 vs. ≥60). RESULTS: The VAS preferences dis-
criminated between severity levels in physical disability in each
of the ﬁve cases against which they were tested. Preferences
ranged from 0.00–0.12 for total dependence (BI = 0–20), from
0.06–0.43 for severe dependence (BI = 25–60), from 0.46–0.84
for moderate dependence (BI = 65–90), and from 0.87–1.00 for
independence (BI = 95–100). For a ﬁve-category physical dis-
ability severity scheme, preferences ranged from 0.00–0.12 for
very severe (BI = 0–20), 0.06–0.30 for severe (BI = 25–45),
0.30–0.69 for moderate (BI = 50–70), 0.59–0.92 for mild phys-
ical disability (BI = 75–95). Preferences associated with modiﬁed
Rankin scores were 0.00–0.18 for category 5 (severe handicap);
0.24–0.46 for category 2 (moderately severe handicap);
0.69–0.84 for category 3 (moderate handicap), and 0.87–1.00
for categories 0–2 (no symptoms to minor handicap). Preferences
for BI scores <95 vs. ≥95 were 0.00–0.84 vs. 0.87–1.00 vs.
respectively, and for BI scores <60 vs. ≥60 were 0.00–0.43 vs.
0.43–1.00, respectively. CONCLUSIONS: VAS preferences were
found to relate directly to disability severity and may be useful
in distinguishing between different physical disability levels in
stroke patients.
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OBJECTIVES: The Cambridge Pulmonary Hypertension
Outcome Review (CAMPHOR) is the ﬁrst validated patient-
completed measure for assessing outcome in Pulmonary Hyper-
tension (PH). It consists of separate scales assessing Overall
Symptoms, Energy Level, Breathlessness, Mood, Physical Func-
tioning and Quality of Life (QoL). This study compares the rel-
ative performance of the CAMPHOR with that of generic
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(Nottingham Health Proﬁle (NHP) and EQ-5D) outcome assess-
ments in PH. METHODS: PH patients completed the instru-
ments in a postal survey. Instruments were compared in terms of
end effects, association with clinical indicators (Six Minute Walk
Test (6MWT) and New York Heart Association class (NYHA))
and ability to discriminate between patients on the basis of
symptom severity and perceived general health. RESULTS:
In total, 91 patients participated (mean (SD) age: 52.6 (16.0),
64% female, mean (SD) duration of PH: 4.8 (6.0) years). End
effects were slight in the CAMPHOR (Energy scale = 10.1%
ﬂoor/11.2% ceiling; Mood 19.3% ﬂoor) but substantial in the
NHP. NHP ﬂoor effects ranged from 54.9% (Pain) to 11.9%
(Physical Mobility) and ceiling effects from 32.5% (Energy) to
0.0% (Pain and Social). NYHA correlations with the NHP
ranged from 0.59 (Physical Mobility) to 0.20 (Pain) and with the
CAMPHOR from 0.60 (Functioning) to 0.47 (Overall Symp-
toms). 6MWT distance correlated 0.71 with CAMPHOR Func-
tioning. All CAMPHOR, NHP (except Sleep) and EQ-5D scales
discriminated between patients based on perceived general health
(p < 0.01). The scales also distinguished between patients accord-
ing to symptom severity (p < 0.01). All CAMPHOR scales
(except Mood) distinguished between NYHA classiﬁcations (p £
0.001). Of the generic measures only the NHP Energy and 
Physical Mobility scales discriminated according to NYHA.
CONCLUSIONS: The CAMPHOR had fewer end effects,
showed closer association with clinical indicators and greater
sensitivity to NYHA class than the generic measures and is 
therefore recommended for assessing outcome in PH.
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OBJECTIVES: To assess the prevalence, awareness, treatment,
and control of hypercholesterolemia among the Chinese Ameri-
cans in New York City. METHODS: This is a community-based
cross-sectional cohort study. Certiﬁed nurses conducted cardio-
vascular disease screenings among 456 Chinese Americans, 64%
women, aged 18 years or older in 2003. Serum total cholesterol
concentration was obtained. Risk factors such as smoking, exer-
cise, blood pressure, body mass index, and waist-to-hip ratio
were also recorded. Hypercholesterolemia is deﬁned as serum
total cholesterol concentration equal to or greater than 200
mg/dL or reported using cholesterol-lowering medications.
Hypercholesterolemia awareness and treatment were assessed
with standardized questions. RESULTS: The age-adjusted 
mean total cholesterol concentration in all study subjects was
198mg/dL (95% CI, 194.28, 200.81) and the prevalence of
hypercholesterolemia in our sample was 56%. Hypercholes-
terolemia awareness, pharmacologic treatment, and control on
pharmacologic treatment were 43%, 16%, and 6%, respectively.
Non-pharmacologic treatment alone accounted for 7%. In a
Pearson correlation analysis, increasing age (p = 0.047) and
blood pressure (both diastolic and systolic, p < 0.001) were inde-
pendently associated with increased rates of serum concentration
of cholesterol; increasing body mass index, waist-to-hip ratio,
exercise, and smoking are not associated with increased in serum
total cholesterol concentrations. CONCLUSIONS: The ﬁndings
suggest that expanded effort is needed to improve hypercholes-
terolemia awareness, treatment, and control. Practitioners may
need to take a more aggressive stance in screening and treating
patients with lipid disorders- with or without existing coronary
heart disease.
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OBJECTIVES: To describe the impact on real conditions of a
treatment’s compliance. METHODS: Between May and July,
2002, 567 GP recruited 1049 female patients spontaneously con-
sulting for CVD. The patients ﬁlled in questionnaires (CIVIQ,
SF12 and Epworth) in order to evaluate the consequences of their
disease. A patients subgroup with RA (treated with ruscus
aculeatus, hespéridine méthyl chalcone HMC & acide ascor-
bique Vit.C ) prescription was identiﬁed. RESULTS: The group
with 2 tablets a day (n = 135) was called the << “non observant
group”: (NOG) >>, the group treated with the recommended
dosage (4 tablets) a day was called “ ‘observant group’: (OG)”
(n = 831). Before treatment, both groups were comparable in
terms of average age (44.1 vs. 45), height and weight (BMI : 24.3
vs. 24.2). The risk factors have been compared: sedentary
lifestyle, family history, underﬂoor heating, pregnancy. None are
signiﬁcant except sedentary lifestyle (NOG 55% vs. 0:66%, p <
0.0001, test ki2). No signiﬁcant difference was observed between
the NOG and the OG: CIVIQ : 34.3 v. 32 , SF12: Physical dimen-
sion: 48.2 v. 46.2, Mental Dimension: 42.5 v. 45, Epworth: 7.2
v. 7.8. After a seven day treatment, the same scales were admin-
istered, in the NOG, no QoL scale improved. In the OG, SF-12
Mental dimension, CIVIQ and Epworth scores signiﬁcantly
improved at D7 (with p respectively < 0.001, = 0.01, < 0.001).
CONCLUSIONS: The compliance with treatment at recom-
mended dosage clearly shows an improvement of speciﬁc and
non speciﬁc quality of life scales at seven days. The future avail-
ability of an RA double dose tablet should improve treatment’s
compliance by decreasing the intakes.
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CVD treatment is based on a double treatment, either conven-
tional (contention or venotonics) or radical (sclerotherapy,
surgery). OBJECTIVES: Describing the venotonic and con-
tention association impact on the patients quality of life.
METHODS: Between May and July, 2002, 567 GP’s recruited
1045 female patients spontaneously consulting for CVD. Two
patient subgroups were identiﬁed: RA (treated with ruscus
aculeatus, hespéridine méthyl chalcone HMC & acide ascor-
bique Vit.C), RAC: (treated with RA and contention). RESULTS:
In both subgroups RA (n = 697) and RAC (n = 269), risk factors
were compared: sedentary lifestyle, family history, underﬂoor
heater, pregnancy. Obesity and family history were found most
often among the RAC patients (25% v. 16% and 50% v. 34%,
p < 0.001 ki2). At inclusion, speciﬁc (CIVIQ), non speciﬁc (SF12)
quality of life (QoL) and daytime sleepiness (Epworth scale) were
evaluated through a self-questionnaire. A total of 304 patients
answered at D0 and D7. No signiﬁcant difference was observed
between the 2 groups RAC v. RA; CIVIQ: 32.3 v. 32.3, SF12:
Physical dimension: 45 v. 46.9, Mental dimension: 43.7 v. 45,
Epworth: 8.4 v. 7.5. After a 7-day treatment, the same scales
were administered. In the RAC group, CIVIQ improved (p =
